SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Reckitt Benckiser Group plc (RBGLY) trades at a trailing P/E of 14.6, forward P/E of 20.4. Trailing earnings yield is 6.87%, forward earnings yield 4.90%. PEG 0.11 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (85/100, Pass) — P/E is below market average (14.6); PEG ≤ 1.0 — Peter Lynch undervalued (0.11); earnings yield beats bond yields (6.87%).
- PEG Ratio 0.11 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 6.87% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 69/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
85/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — RBGLY
Valuation Multiples
P/E (TTM)14.6
Forward P/E20.4
PEG Ratio0.11
Forward PEG1.72
P/B Ratio0.00
P/S Ratio3.25
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.95
Forward EPS (Est.)$0.68
Book Value / Share$0.00
Revenue / Share$4.25
FCF / Share$0.00
Yields & Fair Value
Earnings Yield6.87%
Forward Earnings Yield4.90%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.48 |
$9.48B |
$1.83B |
19.3% |
| 2017 |
$0.95 |
$11.45B |
$3.38B |
29.5% |
| 2018 |
$0.61 |
$12.6B |
$2.16B |
17.2% |
| 2019 |
$-0.78 |
$12.85B |
$-2.77B |
-21.6% |
| 2020 |
$0.33 |
$13.99B |
$1.19B |
8.5% |
| 2021 |
$-0.02 |
$13.23B |
$-63M |
-0.5% |
| 2022 |
$0.65 |
$14.45B |
$2.33B |
16.1% |
| 2023 |
$0.46 |
$14.61B |
$1.64B |
11.2% |
| 2024 |
$0.41 |
$14.17B |
$1.43B |
10.1% |
| 2025 |
$0.95 |
$13.89B |
$3.11B |
22.4% |
